Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354416 | 0.94 | CYP1A2 (0.52) | HPGDTSHRDRD2DRD4DRD3 | |
| SCHEMBL19411968 | 0.89 | ALDH1A1 (0.43) | HPGDTSHRTDP1CYP1A2MAPT | |
| SCHEMBL251644 | 0.84 | ALDH1A1 (0.43) | HPGDTSHRTDP1CYP1A2MAPT | |
| SCHEMBL29448429 | 0.82 | CYP1A2 (0.38) | TSHRTDP1CYP1A2MAPTPTGS2 | |
| SCHEMBL29288587 | 0.82 | LTA4H (0.50) | HPGDTSHRPGRMAPTALDH1A1 | |
| SCHEMBL9818933 | 0.82 | LMNA (0.44) | HPGDCYP1A2MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL8760585 | 0.80 | CYP1A2 (0.41) | TDP1CYP1A2ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL10773638 | 0.80 | ALDH1A1 (0.59) | HPGDTSHRTDP1CYP1A2MAPT | |
| SCHEMBL6510351 | 0.78 | HPGD (0.52) | HPGDTSHRDRD2DRD4DRD3 | |
| SCHEMBL1283610 | 0.78 | HPGD (0.47) | HPGDNOX1MAOBALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113563235-B | Synthetic method of 3- (halogenated phenoxy) benzenesulfonyl chloride derivative | 上海毕得医药科技股份有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-108884032-B | Method for preparing poly (carbonate-etherimide) compounds | PTT全球化学股份有限公司 | 2021-10-15 | — | — | CN | disclosed |
| US-10975062-B2 | 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV | 2021-04-13 | — | — | US | disclosed |
| US-20200095234-A1 | 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-26 | — | — | US | disclosed |
| EP-3551628-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190161471-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2019-05-30 | — | — | US | disclosed |
| US-10246442-B2 | 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-02 | — | — | US | disclosed |
| US-10202362-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| CN-108884032-A | The method for preparing poly- (carbonic ester-etherimide) compound | PTT全球化学股份有限公司 | 2018-11-23 | — | — | CN | disclosed |
| US-20180162836-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
| US-20130143871-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-06 | — | — | US | disclosed |
| US-8372988-B2 | Crystalline forms of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine | TRANSTECH PHARMA, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| WO-2012021830-A1 | 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-16 | — | — | WO | disclosed |
| US-20110166361-A1 | CRYSTALLINE FORMS OF [3-(4- -PHENOXY)-PROPYL]-DIETHYL-AMINE | TRANSTECH PHARMA, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-7884219-B2 | Receptor antagonist of advanced glycosylation endproducts ; antiinflammatory agents; Alzheimer's disease; anticancer, antitumor agent; autoimmune disease; antiarthritic agents; multiple sclerosis; diabetic nephropathy; cardiovascular disorders; osteoporosis | TRANSTECH PHARMA, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-2144883-A1 | CRYSTALLINE FORMS I AND II OF [3-(4-{2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4-YL}-PHENOXY)-PROPYL]-DIETHYL-AMINE | TransTech Pharma, Inc (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008123914-A1 | CRYSTALLINE FORMS I AND II OF [3-(4-{2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4-YL}-PHENOXY)-PROPYL]-DIETHYL-AMINE | TRANSTECH PHARMA, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080249316-A1 | CRYSTALLINE FORMS OF [3-(4- -PHENOXY)-PROPYL]-DIETHYL-AMINE | VTV THERAPEUTICS LLC | 2008-10-09 | — | — | US | disclosed |
| EP-1960347-A2 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | Sterix Limited (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007003934-A2 | 17BETA-HYDR0XYSTER0ID DEHYDROGENASE TYPE 3 (17BETA-HSD3 ) INHIBITORS | STERIX LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975062-B2 | 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | P4HA1, EGLN3, EGLN2 | HPGD 23/4885TSHR 4300/4885DRD2 4636/4885 |
| US-20200095234-A1 | 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | HPGD 23/4885TSHR 4300/4885DRD2 4636/4885 |
| US-20190161471-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | HPGD 240/4885TSHR 2624/4885DRD2 3411/4885 |
| US-20180162836-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | HPGD 240/4885TSHR 2624/4885DRD2 3411/4885 |
| US-10246442-B2 | 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors | P4HA1, EGLN3, EGLN2 | HPGD 37/4885TSHR 4405/4885DRD2 4553/4885 |
| US-10202362-B2 | Inhibitors of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R | HPGD 240/4885TSHR 2624/4885DRD2 3411/4885 |
| US-20130143871-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | HPGD 68/4885TSHR 3890/4885DRD2 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.